DCC

Summary

DCC (DCC netrin 1 receptor, HGNC:2701) is a protein-coding gene on chromosome 18q21.2, encoding Netrin receptor DCC (P43146). Receptor for netrin required for axon guidance.

This gene encodes a netrin 1 receptor. The transmembrane protein is a member of the immunoglobulin superfamily of cell adhesion molecules, and mediates axon guidance of neuronal growth cones towards sources of netrin 1 ligand. The cytoplasmic tail interacts with the tyrosine kinases Src and focal adhesion kinase (FAK, also known as PTK2) to mediate axon attraction. The protein partially localizes to lipid rafts, and induces apoptosis in the absence of ligand. The protein functions as a tumor suppressor, and is frequently mutated or downregulated in colorectal cancer and esophageal carcinoma.

Source: NCBI Gene 1630 — RefSeq curated summary.

At a glance

• Gene–disease (curated): mirror movements 1 and/or agenesis of the corpus callosum (Definitive, ClinGen) — +7 more curated relationships
• GWAS associations: 108
• Clinical variants (ClinVar): 355 total — 36 pathogenic, 17 likely-pathogenic
• Phenotypes (HPO): 93
• Cancer driver (intOGen): loss-of-function (tumor-suppressor-like) across 5 cancer types
• MANE Select transcript: NM_005215

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2701
Approved symbol	DCC
Name	DCC netrin 1 receptor
Location	18q21.2
Locus type	gene with protein product
Status	Approved
Aliases	IGDCC1, NTN1R1
Ensembl gene	ENSG00000187323
Ensembl biotype	protein_coding
OMIM	120470
Entrez	1630

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 6 protein_coding, 6 protein_coding_CDS_not_defined, 3 nonsense_mediated_decay, 2 retained_intron

ENST00000304775, ENST00000442544, ENST00000577224, ENST00000578080, ENST00000578949, ENST00000579349, ENST00000579666, ENST00000579702, ENST00000579883, ENST00000579941, ENST00000580024, ENST00000580146, ENST00000581559, ENST00000581580, ENST00000582595, ENST00000582875, ENST00000584710

RefSeq mRNA: 1 — MANE Select: NM_005215 NM_005215

CCDS: CCDS11952

Canonical transcript exons

ENST00000442544 — 29 exons

Exon	Start	End
ENSE00001128867	53526617	53526759
ENSE00001128875	53499298	53499510
ENSE00001128881	53486797	53486958
ENSE00001128886	53467894	53468010
ENSE00001128891	53459232	53459458
ENSE00001128898	53450500	53450662
ENSE00001128905	53435144	53435209
ENSE00001128911	53416124	53416156
ENSE00001128938	53391655	53391887
ENSE00001128943	53386043	53386138
ENSE00001128947	53339713	53339907
ENSE00001128958	53305578	53305719
ENSE00001128975	53207679	53207817
ENSE00001128981	53205216	53205364
ENSE00001128990	53178962	53179116
ENSE00001129712	52923707	52923857
ENSE00001268586	53530564	53535899
ENSE00001311322	52752054	52752374
ENSE00001314237	53157356	53157512
ENSE00001322608	52340197	52340878
ENSE00001326743	53322047	53322157
ENSE00001344756	53215548	53215597
ENSE00003467698	53397308	53397446
ENSE00003489697	53066046	53066166
ENSE00003493865	53063305	53063459
ENSE00003535823	52925234	52925370
ENSE00003675049	53410452	53410646
ENSE00003676694	53402786	53402893
ENSE00003734028	52906044	52906328

Expression profiles

Bgee: expression breadth ubiquitous, 154 present calls, max score 91.49.

FANTOM5 (CAGE): breadth broad, TPM avg 3.3488 / max 218.7221, expressed in 323 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
170282	1.6430	254
170281	0.8416	218
170285	0.3386	127
170284	0.1306	79
170280	0.1298	79
170278	0.1147	65
170283	0.0938	68
170279	0.0292	12
170291	0.0275	3

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	91.49	gold quality
right testis	UBERON:0004534	86.93	gold quality
left testis	UBERON:0004533	86.41	gold quality
ganglionic eminence	UBERON:0004023	85.40	gold quality
testis	UBERON:0000473	82.83	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.56	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.82	gold quality
prefrontal cortex	UBERON:0000451	70.41	gold quality
Brodmann (1909) area 23	UBERON:0013554	69.28	silver quality
nucleus accumbens	UBERON:0001882	69.15	gold quality
primary visual cortex	UBERON:0002436	69.02	gold quality
caudate nucleus	UBERON:0001873	68.92	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	67.08	gold quality
sperm	CL:0000019	67.03	silver quality
Brodmann (1909) area 9	UBERON:0013540	66.99	gold quality
sural nerve	UBERON:0015488	66.94	gold quality
putamen	UBERON:0001874	66.91	gold quality
cerebral cortex	UBERON:0000956	66.89	gold quality
Ammon’s horn	UBERON:0001954	66.77	gold quality
frontal cortex	UBERON:0001870	66.61	gold quality
frontal lobe	UBERON:0016525	66.60	gold quality
neocortex	UBERON:0001950	66.46	gold quality
ventricular zone	UBERON:0003053	65.91	gold quality
entorhinal cortex	UBERON:0002728	65.90	silver quality
middle temporal gyrus	UBERON:0002771	65.54	silver quality
colonic epithelium	UBERON:0000397	65.24	gold quality
superior frontal gyrus	UBERON:0002661	64.90	gold quality
forebrain	UBERON:0001890	64.87	gold quality
occipital lobe	UBERON:0002021	64.37	gold quality
hypothalamus	UBERON:0001898	63.87	gold quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 8.

Experiment	Marker?	Max mean expression
E-HCAD-30	yes	1776.86
E-CURD-119	yes	1423.60
E-GEOD-131882	yes	1362.32
E-HCAD-25	yes	1319.95
E-GEOD-93593	yes	661.07
E-HCAD-56	yes	659.08
E-HCAD-35	yes	75.62
E-ANND-3	yes	6.70

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): BCL11A, E2F1, PBX1, SATB2, SOX9, TFAP2A, TP53

miRNA regulators (miRDB)

202 targeting DCC, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505

Literature-anchored findings (GeneRIF, showing 40)

• Altered expression of DCC protein is detectable in gastric carcinomas, an event that may have a role in the development of the disease. (PMID:11518545)
• The netrin-1 receptor DCC promotes filopodia formation and cell spreading by activating Cdc42 and Rac1. (PMID:11817894)
• Loss of dcc gene expression is associated with acute myelogenous leukemia (PMID:12060632)
• loss of DCC expression occurs in some colon adenomas, but is insufficient to drive the adenoma to carcinoma progression. (PMID:12432238)
• data suggest that the codon 201 polymorphism of the DCC gene was a target of LOH, and predicted prognosis in colorectal cancer patients (PMID:12787729)
• DCC binds to netrin, which regulates its interactions with heparin (PMID:12810718)
• Prognostic significance of the DCC gene protein expression in high-risk resected gastric carcinoma (PMID:12901278)
• Deletions in this gene are found in colorectal and gastric cancers (PMID:12901294)
• Multiple aberrations involving the DCC locus may play a role in the progression of nephroblastomas, and hence confer a poorer prognosis. (PMID:14631365)
• DCC/netrin-1 signaling may commit cells to the transition of endometrial gland architecture or function from a proliferating to a secretory phase. (PMID:15491747)
• Binding of netrin-1 to its receptors inhibits tumour suppressor p53-dependent apoptosis (review) (PMID:15573119)
• DCC binds netrin through the fourth fibronectin type III domain. (PMID:15574733)
• DCC expression appears not to be predictive in poor survival outcome in patients with stage II or III colorectal cancer. (PMID:15722793)
• DCC in both commissural neurons and immortalized cells, is partially associated with cholesterol- and sphingolipid-enriched membrane domains named lipid rafts. (PMID:15811950)
• The present study points to a potential influence of folates in regulating DCC expression at multiple levels involving post-transcriptional pathways. (PMID:16122883)
• the localization of DCC to lipid rafts is a prerequisite for its proapoptotic activity, both in immortalized cells and in primary neurons (PMID:16537496)
• Finds a linkage between the chromosome 18 near marker D18S851 at the third time point and the levels of HDL cholesterol in human males. (PMID:16715837)
• Results suggest that DCC could regulate cell adhesion and migration through its association with ERM-M (ezrin/radixin/moesin and merlin) proteins. (PMID:16762451)
• Patients with low nuclear DCC expression had a 3-year progression-free survival (PFS) rate of 0% compared with 33% of those with high DCC expression (P = 0.0067). (PMID:16971669)
• DCC is a putative conditional tumor-suppressor gene that is epigenetically inactivated by promoter hypermethylation in a majority of head-and-neck squamous cell carcinomas. (PMID:17018594)
• Overexpression of the DDC gene in the LNCaP prostate cancer cell line leads to differential expression of a total of 35 genes. (PMID:17553164)
• study provides evidence that most colorectal cancers have alterations in both UNC5C and DCC netrin receptors; while UNC5C expression is regulated primarily via epigenetic regulation, DCC defects are mediated through allelic deletions (PMID:18054557)
• DCC methylation is a frequent and cancer-specific event in primary ESCCs (esophageal squamous cell carcinoma), suggesting that DCC and associated pathways may represent a new diagnostical therapeutic target. (PMID:18302152)
• DCC can be found in raft and non-raft portions of the plasma membrane. (PMID:18616430)
• the transcriptionally active TAp73alpha tumor suppressor is implicated in the apoptosis induced by netrin-1 in a p53-independent and DCC/ubiquitin-proteasome dependent manner. (PMID:18922894)
• Aberrant methylation of the netrin-1 receptor genes UNC5C and DCC detected in advanced colorectal cancer. (PMID:19242752)
• Treatment with the demethylating agent 5-aza-2’-deoxycytidine, but not with the histone deacetylase inhibitor trichostatin A exclusively restored DCC expression in CRC cell lines. (PMID:19329758)
• Alterations in TP53, APC, K-ras, and DCC genes in the non-dysplastic ulcerative colitis and Crohn’s disease colon, were analyzed. (PMID:19543899)
• DCC receptor is localized to syncytiotrophoblasts and invasive extravillous cytotrophoblasts during the first trimester and at term. (PMID:19826074)
• Lost expression of DCC gene is associated with ovarian cancer. (PMID:20054719)
• DCC methylation was observed in the course of gastric carcinogenesis and disappeared in advanced gastric carcinoma. (PMID:20150623)
• study found that individuals affected with congenital mirror movements carried protein-truncating mutations in DCC; mutant DCC protein revealed a defect in netrin-1 binding; DCC has an important role in lateralization of the nervous system (PMID:20431009)
• our findings might indicate also an important role for DCC and netrin-1 in human foetal central nervous system development (PMID:20609112)
• study reports a novel DCC gene mutation responsible for congenital isolated persistent mirror movements in an Italian family and provide evidence that this entity is genetically heterogeneous (PMID:21242494)
• An unexpected binding mode of the DCC peptide to the subdomain C groove of the FERM domain, which is distinct from previously reported beta-beta associations found in radixin-adhesion molecule complexes. (PMID:21642953)
• SNP rs7504990 in the DCC showed genome-wide significant association with gallbladder cancer susceptibility. (PMID:22318345)
• The results of this study suggested that DCC as a promising novel candidate gene that may contribute to the genetic basis behind individual differences in susceptibility to schizophrenia. (PMID:22418395)
• Netrin-1 and DCC are increased in diseased lumbar intervertebral discs and may play a role in the process of neurovascular growth. (PMID:22588384)
• Ethnic Malays is genetically susceptible to H. pylori infection and is possibly mediated through a genetic variation in the DCC gene. (PMID:22829558)
• results suggested that cohypermethylation of p14 in combination with DCC and/or CADM1 may be an independent prognostic factor for recurrence in patients with stage I ESCC (PMID:23310950)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	dcc	ENSDARG00000104282
mus_musculus	Dcc	ENSMUSG00000060534
rattus_norvegicus	Dcc	ENSRNOG00000033099

Paralogs (36): CNTN1 (ENSG00000018236), CDON (ENSG00000064309), NEO1 (ENSG00000067141), SDK2 (ENSG00000069188), IGSF9B (ENSG00000080854), IGSF9 (ENSG00000085552), NRCAM (ENSG00000091129), MXRA5 (ENSG00000101825), IGDCC4 (ENSG00000103742), CNTN3 (ENSG00000113805), IGSF21 (ENSG00000117154), CNTN6 (ENSG00000134115), CHL1 (ENSG00000134121), PTPRQ (ENSG00000139304), CNTN4 (ENSG00000144619), BOC (ENSG00000144857), SDK1 (ENSG00000146555), HMCN2 (ENSG00000148357), NCAM1 (ENSG00000149294), CNTN5 (ENSG00000149972), IGSF10 (ENSG00000152580), ROBO4 (ENSG00000154133), ROBO3 (ENSG00000154134), NCAM2 (ENSG00000154654), VCAM1 (ENSG00000162692), NFASC (ENSG00000163531), PRTG (ENSG00000166450), ROBO1 (ENSG00000169855), DSCAM (ENSG00000171587), IGDCC3 (ENSG00000174498), VSIG10 (ENSG00000176834), DSCAML1 (ENSG00000177103), CNTN2 (ENSG00000184144), ROBO2 (ENSG00000185008), VSIG10L (ENSG00000186806), L1CAM (ENSG00000198910)

Protein

Protein identifiers

Netrin receptor DCC — P43146 (reviewed: P43146)

Alternative names: Colorectal cancer suppressor, Immunoglobulin superfamily DCC subclass member 1, Tumor suppressor protein DCC

All UniProt accessions (9): P43146, H0Y2Q5, J3QKL2, J3QLB0, J3QLT8, J3QQJ6, J3QRL3, J3QRM6, J3QS93

UniProt curated annotations — full annotation on UniProt →

Function. Receptor for netrin required for axon guidance. Mediates axon attraction of neuronal growth cones in the developing nervous system upon ligand binding. Its association with UNC5 proteins may trigger signaling for axon repulsion. It also acts as a dependence receptor required for apoptosis induction when not associated with netrin ligand. Implicated as a tumor suppressor gene.

Subunit / interactions. Interacts with the cytoplasmic part of UNC5A, UNC5B, UNC5C and probably UNC5D. Interacts with DSCAM. Interacts with PTK2/FAK1 and MAPK1. Interacts with NTN1. Interacts with MYO10. Interacts with CBLN4; this interaction can be competed by NTN1. Interacts with SIAH1 and SIAH2.

Subcellular location. Membrane.

Tissue specificity. Found in axons of the central and peripheral nervous system and in differentiated cell types of the intestine. Not expressed in colorectal tumor cells that lost their capacity to differentiate into mucus producing cells.

Post-translational modifications. Ubiquitinated; mediated by SIAH1 or SIAH2 and leading to its subsequent proteasomal degradation.

Disease relevance. Mirror movements 1 (MRMV1) [MIM:157600] A disorder characterized by contralateral involuntary movements that mirror voluntary ones. While mirror movements are occasionally found in young children, persistence beyond the age of 10 is abnormal. Mirror movements occur more commonly in the upper extremities. Some MRMV1 patients have agenesis of the corpus callosum. The disease is caused by variants affecting the gene represented in this entry. Gaze palsy, familial horizontal, with progressive scoliosis, 2, with impaired intellectual development (HGPPS2) [MIM:617542] An autosomal recessive neurologic disorder characterized by global developmental delay, delayed walking, intellectual disability, horizontal gaze palsy, and childhood-onset progressive scoliosis. The disease is caused by variants affecting the gene represented in this entry.

Miscellaneous. Inactivation of DCC due to allelic deletion and/or point mutations is related to lymphatic and hematogenous metastatic tumor dissemination.

Similarity. Belongs to the immunoglobulin superfamily. DCC family.

RefSeq proteins (1): NP_005206* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR003961	FN3_dom	Domain
IPR007110	Ig-like_dom	Domain
IPR010560	Neogenin_C	Domain
IPR013098	Ig_I-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036116	FN3_sf	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily

Pfam: PF00041, PF06583, PF07679

UniProt features (123 total): strand 51, sequence variant 27, domain 10, glycosylation site 6, region of interest 5, disulfide bond 4, helix 3, compositionally biased region 3, modified residue 3, mutagenesis site 3, topological domain 2, turn 2, signal peptide 1, chain 1, transmembrane region 1, sequence conflict 1

Structure

Experimental structures (PDB)

9 structures.

PDB	Method	Resolution (Å)
3AU4	X-RAY DIFFRACTION	1.9
5X83	X-RAY DIFFRACTION	3
4URT	X-RAY DIFFRACTION	3.1
2ED7	SOLUTION NMR
2ED8	SOLUTION NMR
2ED9	SOLUTION NMR
2EDB	SOLUTION NMR
2EDD	SOLUTION NMR
2EDE	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P43146-F1	68.60	0.26

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 1178, 1187, 1267

Disulfide bonds (4): 61–117, 161–212, 261–310, 352–400

Glycosylation sites (6): 94, 299, 318, 478, 628, 702

Mutagenesis-validated functional residues (3):

Position	Phenotype
1432	abolishes interaction with myo10.
1435–1436	abolishes interaction with myo10.
1439	abolishes interaction with myo10.

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-373752	Netrin-1 signaling
R-HSA-376172	DSCAM interactions
R-HSA-418885	DCC mediated attractive signaling
R-HSA-418886	Netrin mediated repulsion signals
R-HSA-418889	Caspase activation via Dependence Receptors in the absence of ligand
R-HSA-418890	Role of second messengers in netrin-1 signaling
R-HSA-428542	Regulation of commissural axon pathfinding by SLIT and ROBO

MSigDB gene sets: 401 (showing top): GOBP_SPINAL_CORD_DEVELOPMENT, GOBP_DENDRITE_DEVELOPMENT, GOBP_NEGATIVE_REGULATION_OF_CELL_DEVELOPMENT, GOBP_REGULATION_OF_COLLATERAL_SPROUTING, BENPORATH_ES_WITH_H3K27ME3, GOBP_REGULATION_OF_DEVELOPMENTAL_GROWTH, PID_NETRIN_PATHWAY, GOBP_NEGATIVE_REGULATION_OF_CELL_GROWTH, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GOBP_GROWTH, GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_DN, GOCC_CELL_SURFACE, SCHLESINGER_METHYLATED_DE_NOVO_IN_CANCER, GOBP_NEUROGENESIS, GOBP_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT

GO Biological Process (12): neuron migration (GO:0001764), apoptotic process (GO:0006915), axonogenesis (GO:0007409), axon guidance (GO:0007411), negative regulation of neuron projection development (GO:0010977), spinal cord ventral commissure morphogenesis (GO:0021965), dorsal/ventral axon guidance (GO:0033563), anterior/posterior axon guidance (GO:0033564), negative regulation of collateral sprouting (GO:0048671), cell-cell adhesion (GO:0098609), postsynaptic modulation of chemical synaptic transmission (GO:0099170), negative regulation of dendrite development (GO:2000171)

GO Molecular Function (2): transmembrane signaling receptor activity (GO:0004888), protein binding (GO:0005515)

GO Cellular Component (7): cytosol (GO:0005829), plasma membrane (GO:0005886), cell surface (GO:0009986), axon (GO:0030424), Schaffer collateral - CA1 synapse (GO:0098685), postsynaptic density membrane (GO:0098839), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Netrin-1 signaling	4
Axon guidance	1
Caspase activation via extrinsic apoptotic signalling pathway	1
Signaling by ROBO receptors	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
axon guidance	2
cell migration	1
generation of neurons	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
cell morphogenesis involved in neuron differentiation	1
neuron projection morphogenesis	1
axon development	1
axonogenesis	1
neuron projection guidance	1
regulation of neuron projection development	1
neuron projection development	1
negative regulation of cell projection organization	1
spinal cord development	1
central nervous system projection neuron axonogenesis	1
negative regulation of cell growth	1
negative regulation of developmental growth	1
collateral sprouting	1
regulation of collateral sprouting	1
negative regulation of axonogenesis	1
cell adhesion	1
modulation of chemical synaptic transmission	1
postsynapse	1
negative regulation of neuron projection development	1
dendrite development	1
regulation of dendrite development	1
negative regulation of developmental process	1
signaling receptor activity	1
binding	1
cytoplasm	1
membrane	1
cell periphery	1
neuron projection	1
synapse	1
postsynaptic density	1
postsynaptic membrane	1
postsynaptic specialization membrane	1

Protein interactions and networks

STRING

1150 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DCC	NTN1	O95631	999
DCC	UNC5B	Q8IZJ1	816
DCC	SLIT3	O75094	747
DCC	NTN4	Q9HB63	742
DCC	SLIT2	O94813	708
DCC	TRIM9	Q9C026	693
DCC	UNC5D	Q6UXZ4	675
DCC	DSCAM	O60469	663
DCC	ALOX12	P18054	638
DCC	CBLN4	Q9NTU7	631
DCC	SLIT1	O75093	620
DCC	UNC5A	Q6ZN44	620
DCC	RPL5	P46777	603
DCC	ROBO2	Q9HCK4	598
DCC	ROBO1	Q9Y6N7	595

IntAct

62 interactions, top by confidence:

A	B	Type	Score
CNOT6L	CNOT1	psi-mi:“MI:0914”(association)	0.810
DCC	NTN1	psi-mi:“MI:0915”(physical association)	0.700
DCC	NTN1	psi-mi:“MI:0407”(direct interaction)	0.700
DCC	NTN1	psi-mi:“MI:0914”(association)	0.700
DCC	MYO10	psi-mi:“MI:0407”(direct interaction)	0.650
MYO10	DCC	psi-mi:“MI:0915”(physical association)	0.650
DCC	RPL5	psi-mi:“MI:0915”(physical association)	0.610
DCC	CASP9	psi-mi:“MI:0915”(physical association)	0.590
CASP9	DCC	psi-mi:“MI:0915”(physical association)	0.590
DCC	IGFBPL1	psi-mi:“MI:0915”(physical association)	0.540
DCC	PSG7	psi-mi:“MI:0915”(physical association)	0.540
IGFBPL1	DCC	psi-mi:“MI:0915”(physical association)	0.540
PSG7	DCC	psi-mi:“MI:0407”(direct interaction)	0.540
DCC	IGFBPL1	psi-mi:“MI:0407”(direct interaction)	0.540
MAZ	DCC	psi-mi:“MI:0915”(physical association)	0.510
DCC	MAZ	psi-mi:“MI:0915”(physical association)	0.510
RPL28	DCC	psi-mi:“MI:0914”(association)	0.460
DCC	NTN4	psi-mi:“MI:0407”(direct interaction)	0.440
LTF	DCC	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (121): AR (Affinity Capture-Western), AR (Reconstituted Complex), AR (Two-hybrid), DCC (Affinity Capture-Western), DCC (Affinity Capture-Western), PTK2 (Affinity Capture-Western), DCC (Affinity Capture-Western), DCC (Affinity Capture-Western), DCC (Positive Genetic), NTN1 (Reconstituted Complex), RRBP1 (Proximity Label-MS), CASP3 (Two-hybrid), DCC (Affinity Capture-Western), DCC (Affinity Capture-Western), DCC (Reconstituted Complex)

ESM2 similar proteins: D3ZB51, E9PZ19, O60245, O94779, P13590, P13591, P13595, P13596, P14781, P24786, P31836, P33150, P43146, P55290, P68500, P70211, P97300, P97527, P97528, P97546, P97603, P97798, Q07409, Q0E9H9, Q16288, Q3B7N0, Q5IFJ9, Q5IS37, Q5IS82, Q5R5W6, Q62682, Q62845, Q63155, Q69Z26, Q6AZB0, Q6VNS1, Q7TPD3, Q7ZW34, Q8IWV2, Q90610

Diamond homologs: A0A087WV53, A1KZ92, A2AJ76, A4IFW2, A4IGL7, A6NDA9, B0BNK7, B0V2N1, D2HFT7, D3YXG0, D4A1J9, D4ABX8, F1NWE3, G5EG78, O15146, O73775, O75325, O94898, P07722, P15364, P20916, P20917, P23468, P43146, P48960, P53813, P70193, P70211, Q03142, Q08761, Q08879, Q13332, Q13449, Q1ENI8, Q1RMS4, Q1WIM1, Q21038, Q24372, Q26474, Q2Q421

SIGNOR signaling

20 interactions.

A	Effect	B	Mechanism
SOX9	“up-regulates quantity by expression”	DCC	“transcriptional regulation”
TFAP2A	“up-regulates quantity by expression”	DCC	“transcriptional regulation”
NTN1	“up-regulates activity”	DCC	binding
DCC	up-regulates	Chemoattraction_of_axon
UNC5A	“down-regulates activity”	DCC	binding
UNC5C	“down-regulates activity”	DCC	binding
UNC5B	“down-regulates activity”	DCC	binding
UNC5D	“down-regulates activity”	DCC	binding
UNC5	“down-regulates activity”	DCC	binding
DCC	“up-regulates activity”	CACNA1C
DCC	“up-regulates activity”	CACNA1D
DCC	“up-regulates activity”	CACNA1A
DCC	“up-regulates activity”	PTK2	binding
DCC	“up-regulates activity”	SRC	binding
FYN	“up-regulates activity”	DCC	phosphorylation
DCC	“up-regulates activity”	MYO10	binding
MYO10	“up-regulates quantity”	DCC	relocalization
TRIO	“up-regulates quantity”	DCC	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 43 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Response of EIF2AK4 (GCN2) to amino acid deficiency	5	17.9×	8e-04
L13a-mediated translational silencing of Ceruloplasmin expression	5	16.3×	8e-04
GTP hydrolysis and joining of the 60S ribosomal subunit	5	16.2×	8e-04
Axon guidance	6	8.7×	3e-03
Nervous system development	6	8.3×	3e-03

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: loss-of-function (tumor-suppressor-like) across 5 cancer types — COADREAD, ESCA, HCC, PAAD, PRAD.

Clinical variants and AI predictions

ClinVar

355 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	36
Likely pathogenic	17
Uncertain significance	205
Likely benign	48
Benign	19

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1072844	NM_005215.4(DCC):c.3682C>T (p.Arg1228Ter)	Pathogenic
1300257	NM_005215.4(DCC):c.2774dup (p.Asn925fs)	Pathogenic
1676259	NM_005215.4(DCC):c.2266C>T (p.Arg756Ter)	Pathogenic
17074	NM_005215.4(DCC):c.4124C>A (p.Pro1375His)	Pathogenic
17075	NM_005215.4(DCC):c.503T>C (p.Met168Thr)	Pathogenic
187795	NM_005215.4(DCC):c.571dup (p.Val191fs)	Pathogenic
187796	NM_005215.4(DCC):c.823C>T (p.Arg275Ter)	Pathogenic
187797	NM_005215.4(DCC):c.1140+1G>A	Pathogenic
187800	NM_005215.4(DCC):c.3836_3837del (p.Leu1279fs)	Pathogenic
187801	NM_005215.3(DCC):c.698-?_985+?del (p.Asp233_Leu328del)	Pathogenic
2229313	NM_005215.4(DCC):c.3061C>T (p.Arg1021Ter)	Pathogenic
2429879	NM_005215.4(DCC):c.1154T>A (p.Leu385Ter)	Pathogenic
2473854	NM_005215.4(DCC):c.2540del (p.Pro847fs)	Pathogenic
2498740	NM_005215.4(DCC):c.965_966dup (p.Ala323fs)	Pathogenic
2500956	NM_005215.4(DCC):c.1573+2T>G	Pathogenic
2626888	NM_005215.4(DCC):c.2280_2286del (p.Ile760fs)	Pathogenic
3027383	NM_005215.4(DCC):c.2205_2207delinsATGAT (p.Pro736Ter)	Pathogenic
3376699	NM_005215.4(DCC):c.2377_2381del (p.Val793fs)	Pathogenic
3377513	NM_005215.4(DCC):c.3577C>T (p.Gln1193Ter)	Pathogenic
375281	NM_005215.4(DCC):c.925del (p.Thr309fs)	Pathogenic
375282	NM_005215.4(DCC):c.2378T>G (p.Val793Gly)	Pathogenic
375283	NM_005215.4(DCC):c.2414G>A (p.Gly805Glu)	Pathogenic
375284	NM_005215.4(DCC):c.1790G>C (p.Arg597Pro)	Pathogenic
375287	NM_005215.4(DCC):c.2677G>A (p.Ala893Thr)	Pathogenic
3899221	NM_005215.4(DCC):c.278C>A (p.Ser93Ter)	Pathogenic
446724	NM_005215.4(DCC):c.788_794del (p.Val263fs)	Pathogenic
446759	NM_005215.4(DCC):c.31_91+7622del	Pathogenic
4532371	NM_005215.4(DCC):c.2635C>T (p.Arg879Ter)	Pathogenic
4832987	NM_005215.4(DCC):c.2353_2354dup (p.Leu786fs)	Pathogenic
4845332	NM_005215.4(DCC):c.2690C>G (p.Ser897Ter)	Pathogenic

SpliceAI

3799 predictions. Top by Δscore:

Variant	Effect	Δscore
18:52392899:G:GT	donor_gain	1.0000
18:52752050:CCA:C	acceptor_loss	1.0000
18:52752051:CA:C	acceptor_loss	1.0000
18:52752052:A:AG	acceptor_gain	1.0000
18:52752053:G:GG	acceptor_gain	1.0000
18:52752226:G:GT	donor_gain	1.0000
18:52752370:AGCAG:A	donor_loss	1.0000
18:52752372:CAGGT:C	donor_loss	1.0000
18:52752373:AGG:A	donor_loss	1.0000
18:52752374:GGTA:G	donor_loss	1.0000
18:52752375:GTA:G	donor_loss	1.0000
18:52752376:T:G	donor_loss	1.0000
18:52906040:CTA:C	acceptor_loss	1.0000
18:52906042:A:AG	acceptor_gain	1.0000
18:52906042:AG:A	acceptor_gain	1.0000
18:52906043:G:GA	acceptor_gain	1.0000
18:52906043:GG:G	acceptor_gain	1.0000
18:52906043:GGACC:G	acceptor_gain	1.0000
18:52906324:ATCAG:A	donor_loss	1.0000
18:52906325:TCAG:T	donor_loss	1.0000
18:52906326:CAG:C	donor_loss	1.0000
18:52906327:AG:A	donor_loss	1.0000
18:52906328:GG:G	donor_loss	1.0000
18:52906329:G:A	donor_loss	1.0000
18:52906330:T:A	donor_loss	1.0000
18:52340875:ACCGG:A	donor_loss	0.9900
18:52340876:CCGG:C	donor_loss	0.9900
18:52340877:CGG:C	donor_loss	0.9900
18:52340879:G:GG	donor_gain	0.9900
18:52340880:T:A	donor_loss	0.9900

AlphaMissense

9393 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
18:52752182:T:A	W74R	1.000
18:52752182:T:C	W74R	1.000
18:52752184:G:C	W74C	1.000
18:52752184:G:T	W74C	1.000
18:52906150:G:C	W173C	1.000
18:52906150:G:T	W173C	1.000
18:53063409:T:A	W364R	1.000
18:53063409:T:C	W364R	1.000
18:53063411:G:C	W364C	1.000
18:53063411:G:T	W364C	1.000
18:52752183:G:C	W74S	0.999
18:52752305:T:G	Y115D	0.999
18:52906148:T:A	W173R	0.999
18:52906148:T:C	W173R	0.999
18:52906149:G:C	W173S	0.999
18:52906259:T:G	Y210D	0.999
18:52923826:T:A	W273R	0.999
18:52923826:T:C	W273R	0.999
18:53063410:G:C	W364S	0.999
18:53066097:T:G	Y398D	0.999
18:53066103:T:C	C400R	0.999
18:53066105:T:G	C400W	0.999
18:53157428:T:A	V445D	0.999
18:53157439:T:A	W449R	0.999
18:53157439:T:C	W449R	0.999
18:53157485:T:A	V464D	0.999
18:53179042:T:C	F500S	0.999
18:53179048:T:A	V502D	0.999
18:53205284:T:A	W548R	0.999
18:53205284:T:C	W548R	0.999

dbSNP variants (sampled 300 via entrez): RS1000001379 (18:52859003 T>C), RS1000002772 (18:52966775 C>G,T), RS1000004801 (18:52774919 T>C), RS1000006237 (18:52360112 A>G), RS1000008397 (18:52818573 C>T), RS1000008414 (18:53004191 C>T), RS1000009595 (18:53194411 C>A), RS1000009623 (18:52925572 C>T), RS1000012093 (18:53115613 A>G), RS1000012313 (18:53188068 G>T), RS1000013002 (18:52936381 G>C), RS1000015148 (18:52850076 T>C), RS1000019453 (18:53077171 G>A), RS1000019999 (18:52673937 G>A), RS1000022239 (18:52400393 G>A)

Disease associations

OMIM: gene MIM:120470 | disease phenotypes: MIM:157600, MIM:114500, MIM:617542, MIM:217990, MIM:133239

GenCC curated gene-disease

Disease	Classification	Inheritance
mirror movements 1	Definitive	Autosomal dominant
gaze palsy, familial horizontal, with progressive scoliosis, 2	Strong	Autosomal recessive
connective tissue disorder	Moderate	Autosomal recessive
familial congenital mirror movements	Supportive	Autosomal dominant
Kallmann syndrome	Supportive	Autosomal dominant
colorectal cancer	No Known Disease Relationship	Unknown
esophageal cancer	No Known Disease Relationship	Unknown

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
mirror movements 1 and/or agenesis of the corpus callosum	Definitive	AD

Mondo (12): mirror movements 1 (MONDO:0008002), colorectal cancer (MONDO:0005575), gaze palsy, familial horizontal, with progressive scoliosis, 2 (MONDO:0054602), mirror movements 1 and/or agenesis of the corpus callosum (MONDO:0100515), amenorrhea (MONDO:0001836), colon carcinoma (MONDO:0002032), corpus callosum, agenesis of (MONDO:0009022), autism spectrum disorder (MONDO:0005258), esophageal cancer (MONDO:0007576), connective tissue disorder (MONDO:0003900), familial congenital mirror movements (MONDO:0016558), Kallmann syndrome (MONDO:0018800)

Orphanet (5): Familial congenital mirror movements (Orphanet:238722), Isolated corpus callosum agenesis (Orphanet:200), Squamous cell carcinoma of the esophagus (Orphanet:99977), NON RARE IN EUROPE: Colorectal cancer (Orphanet:466667), NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

93 total (30 of 93 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000007	Autosomal recessive inheritance
HP:0000008	Abnormal morphology of female internal genitalia
HP:0000028	Cryptorchidism
HP:0000044	Hypogonadotropic hypogonadism
HP:0000054	Micropenis
HP:0000104	Renal agenesis
HP:0000144	Decreased fertility
HP:0000175	Cleft palate
HP:0000238	Hydrocephalus
HP:0000252	Microcephaly
HP:0000407	Sensorineural hearing impairment
HP:0000458	Anosmia
HP:0000470	Short neck
HP:0000486	Strabismus
HP:0000505	Visual impairment
HP:0000508	Ptosis
HP:0000551	Color vision defect
HP:0000639	Nystagmus
HP:0000750	Delayed speech and language development
HP:0000771	Gynecomastia
HP:0000786	Primary amenorrhea
HP:0000823	Delayed puberty
HP:0000830	Anterior hypopituitarism
HP:0001249	Intellectual disability
HP:0001250	Seizure
HP:0001251	Ataxia
HP:0001252	Hypotonia
HP:0001256	Mild intellectual disability
HP:0001260	Dysarthria

GWAS associations

108 associations (top):

Study	Trait	p-value
GCST001053_6	Alcoholism (alcohol use disorder factor score)	8.000000e-06
GCST001404_1	Gallbladder cancer	7.000000e-08
GCST001762_102	Obesity-related traits	5.000000e-07
GCST002157_8	Response to mTOR inhibitor (everolimus)	9.000000e-06
GCST002726_16	Glucose homeostasis traits	8.000000e-06
GCST002756_2	Subcortical brain region volumes	1.000000e-13
GCST002928_18	Nickel levels	3.000000e-06
GCST003207_1	Response to exercise (triglyceride level interaction)	3.000000e-06
GCST003230_2	Survival in colorectal cancer (distant metastatic)	2.000000e-06
GCST003230_4	Survival in colorectal cancer (distant metastatic)	2.000000e-06
GCST003487_7	Response to fenofibrate (total cholesterol levels)	2.000000e-06
GCST003523_23	Coenzyme Q10 levels	2.000000e-07
GCST003769_2	Depression	1.000000e-08
GCST003779_1	Smoking behaviour (cigarettes smoked per day)	3.000000e-06
GCST003964_4	Bortezomib-induced peripheral neuropathy in multiple myeloma	9.000000e-06
GCST004586_3	Body mass index (ever vs never smoking interaction)	5.000000e-06
GCST004863_85	Mosquito bite size	7.000000e-06
GCST004904_197	Body mass index	4.000000e-08
GCST005083_9	Putamen volume	4.000000e-12
GCST005141_29	Cognitive ability (MTAG)	6.000000e-11
GCST005142_44	Cognitive ability	4.000000e-07
GCST005237_4	Mood instability	1.000000e-07
GCST005238_4	Mood instability	3.000000e-09
GCST005316_221	Intelligence (MTAG)	7.000000e-14
GCST005316_222	Intelligence (MTAG)	6.000000e-13
GCST005316_223	Intelligence (MTAG)	1.000000e-08
GCST005316_224	Intelligence (MTAG)	9.000000e-16
GCST005316_225	Intelligence (MTAG)	2.000000e-09
GCST005316_226	Intelligence (MTAG)	2.000000e-15
GCST005316_227	Intelligence (MTAG)	1.000000e-11

EFO canonical traits (32, from GWAS)

EFO ID	Trait name
EFO:0005189	respiratory quotient
EFO:0005417	response to mTOR inhibitor
EFO:0006830	insulin metabolic clearance rate measurement
EFO:0007681	triglyceride change measurement
EFO:0007768	response to exercise
EFO:0000714	survival time
EFO:0007675	metastasis measurement
EFO:0007806	total cholesterol change measurement
EFO:0007836	coenzyme Q10 measurement
EFO:0007006	depressive symptom measurement
EFO:0006525	cigarettes per day measurement
EFO:0004340	body mass index
EFO:0008378	mosquito bite reaction size measurement
EFO:0004337	intelligence
EFO:0004784	self reported educational attainment
EFO:0008475	mood instability measurement
EFO:0004312	vital capacity
EFO:0007660	neuroticism measurement
EFO:0009598	feeling miserable measurement
EFO:0009588	feeling “fed-up” measurement
EFO:0008579	risk-taking behaviour
EFO:0004318	smoking behavior
EFO:0009749	age at first sexual intercourse measurement
EFO:0004335	short-term memory
EFO:0004695	intraocular pressure measurement
EFO:0010100	multisite chronic pain
EFO:0009695	household income
EFO:0004346	neuroimaging measurement
EFO:0005670	smoking initiation
EFO:0005665	white matter hyperintensity measurement

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D061085	Agenesis of Corpus Callosum	C10.500.034; C16.131.666.034; C23.300.008
D000568	Amenorrhea	C23.550.568.500
D003240	Connective Tissue Diseases	C17.300
D017436	Kallmann Syndrome	C12.050.351.875.253.096.750; C12.200.706.316.096.750; C12.800.316.096.750; C16.131.939.316.096.750; C16.320.467; C19.391.119.096.750; C19.391.482.600

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, decreases expression	6
trichostatin A	affects cotreatment, increases expression, affects expression, decreases reaction	4
entinostat	increases expression, affects cotreatment	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	2
Vorinostat	affects cotreatment, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
taxifolin	increases expression	1
bisphenol A	affects cotreatment, increases methylation, decreases methylation	1
ascorbate-2-phosphate	affects cotreatment, increases expression, affects binding	1
terbufos	increases methylation	1
11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid	affects methylation, increases abundance	1
sodium arsenite	affects methylation	1
rutecarpine	decreases expression	1
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid	affects cotreatment, increases expression	1
CGP 52608	increases reaction, affects binding	1
Chir 99021	affects cotreatment, increases expression, affects binding	1
belinostat	increases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, increases expression	1
XAV939	affects binding, affects cotreatment, increases expression	1
LDN 193189	affects cotreatment, increases expression	1
3-(4-pyridyl)-1H-indole	increases expression, affects cotreatment	1
Decitabine	increases expression	1
Arsenic Trioxide	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Ascorbic Acid	affects binding, affects cotreatment, increases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Cannabinoids	increases abundance, affects methylation	1
Diethylstilbestrol	increases expression	1
Fonofos	increases methylation	1
Fluorouracil	affects cotreatment, increases response to substance	1

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_7066	Ma-26	Cancer cell line	Male
CVCL_B8EJ	Abcam HCT 116 DCC KO	Cancer cell line	Male
CVCL_B8UM	Abcam MCF-7 DCC KO	Cancer cell line	Female
CVCL_B9GS	Abcam A-549 DCC KO	Cancer cell line	Male

Clinical trials (associated diseases)

383 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01042158	PHASE4	COMPLETED	A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
NCT03688191	PHASE4	UNKNOWN	Study of Sirolimus in CTD-TP in China
NCT04169100	PHASE4	UNKNOWN	Novel Form of Acquired Long QT Syndrome
NCT04197050	PHASE4	UNKNOWN	Effect of Sacubitril/Valsartan on Reduced Right Ventricular Ejection Fraction in Patients With CTD
NCT04928586	PHASE4	UNKNOWN	Immunosuppressant Combined With Pirfenidone in CTD-ILD
NCT05440240	PHASE4	RECRUITING	Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren’s Contracture
NCT05505409	PHASE4	UNKNOWN	Efficacy and Safety of Pirfenidone in CTD-ILD
NCT06499233	PHASE4	RECRUITING	Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease
NCT00114829	PHASE4	UNKNOWN	Preoperative Assessment of Colon Tumor
NCT00114842	PHASE4	COMPLETED	Magnetic Resonance (MR) Colonography With Fecal Tagging
NCT00114946	PHASE4	TERMINATED	A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer
NCT00122720	PHASE4	COMPLETED	The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery
NCT00129870	PHASE4	TERMINATED	CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer
NCT00138060	PHASE4	COMPLETED	Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants
NCT00216424	PHASE4	TERMINATED	Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma
NCT00327093	PHASE4	TERMINATED	Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases
NCT00332943	PHASE4	COMPLETED	MR Colonography With Fecal Tagging. Barium vs. BariumFerumoxsil
NCT00441311	PHASE4	COMPLETED	Dissemination of Colorectal Cancer Screening to Primary Care Physicians
NCT00460837	PHASE4	WITHDRAWN	Comparison of Bowel Preparation in Virtual Colonoscopy (VC) - Patient Experience
NCT00473980	PHASE4	COMPLETED	Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients
NCT00488904	PHASE4	COMPLETED	Omega-3 Fatty Acids and Postoperative Complications After Colorectal Surgery
NCT00496678	PHASE4	COMPLETED	Trial of Patient Navigation-Activation
NCT00502671	PHASE4	COMPLETED	A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.
NCT00559676	PHASE4	COMPLETED	Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
NCT00577031	PHASE4	COMPLETED	OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.
NCT00626054	PHASE4	COMPLETED	Comparison of Two Methods of Administration of a PEG Solution
NCT00812864	PHASE4	COMPLETED	Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)
NCT00868569	PHASE4	UNKNOWN	Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer
NCT00868816	PHASE4	COMPLETED	Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles
NCT00874406	PHASE4	UNKNOWN	Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer
NCT00928928	PHASE4	COMPLETED	Oxidative Stress Markers in Open and Laparoscopic Colectomy for Cancer
NCT00942461	PHASE4	COMPLETED	Inflammatory Response in Laparoscopic and Open Colectomy
NCT01023633	PHASE4	UNKNOWN	OPTIMOX1 in Chinese mCRC Patients
NCT01271582	PHASE4	UNKNOWN	Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
NCT01315990	PHASE4	UNKNOWN	FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema
NCT01493713	PHASE4	COMPLETED	Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer
NCT01609660	PHASE4	COMPLETED	Impact of Probiotics on the Intestinal Microbiota
NCT01641458	PHASE4	COMPLETED	Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients
NCT01689792	PHASE4	COMPLETED	A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)
NCT01695772	PHASE4	COMPLETED	A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer